Evidence map›Paper›PMID 40764724›Full record

ArticleScientific reports2025

Resolvin D1 improves bleomycin-induced alveolar maturation arrest in newborn rats.

Jun Shinohara, Tohru Ogihara, Shigeo Yamaoka, Yutaro Kawamura, Daisuke Nishioka, Kazumi Honda, Yumiko Yoshimura, Akira Ashida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun ShinoharaDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.
Tohru OgiharaDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan. tohru.ogihara@ompu.ac.jp.
Shigeo YamaokaDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.
Yutaro KawamuraDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.
Daisuke NishiokaDepartment of Medical Statistics, Osaka Medical and Pharmaceutical University, Research & Development Center, Takatsuki, Osaka, Japan.
Kazumi HondaDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.
Yumiko YoshimuraDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.
Akira AshidaDivision of Neonatology, Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-Machi, TakatsukiOsaka, 569-0801, Japan.

Funding

JSPS KAKENHI JP25461657
6 · The paper itself

Abstract

Sustained, non-resolving inflammation is a fundamental mechanism that causes bronchopulmonary dysplasia (BPD). Specialized pro-resolving mediators (SPMs) are attracting attention as the new endogenous anti-inflammatory agents because they facilitate only the resolution phase of inflammation without affecting its acute phase, indispensable for the elimination of noxious microorganisms and damaged tissues. The preventive effects of resolvin D1 (RvD1), an SPM, were analyzed using bleomycin (Bleo)-induced BPD model of neonatal rats. Starting from the postnatal day (PD)-0, Bleo and RvD1 were administered simultaneously. At PD-14, morphological and immunohistochemical analyses, and the expression of key genes suspected to be involved in the Bleo-induced lung damage, were examined. Bleo injection successfully recapitulated the pathological features of BPD, such as alveolar enlargement and simplification with septal thickening. RvD1 effectively inhibited such alveolar dysmorphogenesis with attenuating macrophage infiltration and restoring the arrested capillary growth. It significantly suppressed the Bleo-induced upregulation of insulin-like growth factor-1 (IGF-1), tenascin-C, elastin, and anillin. The changes in IGF-1 protein expression in the bronchial and alveolar epithelia were confirmed by immunostaining. RvD1 effectively improves Bleo-induced model of alveolar maturation arrest of BPD. The supplementation of SPMs including RvD1 seems to be a promising treatment for the infants with BPD.

Indexed as

BleomycinBronchopulmonary DysplasiaDocosahexaenoic AcidsPulmonary AlveoliAnimalsAnimals, NewbornDisease Models, AnimalInsulin-Like Growth Factor IRatsRats, Sprague-DawleyBleomycinDocosahexaenoic AcidsInsulin-Like Growth Factor Iresolvin D1Bronchopulmonary dysplasiaInsulin-like growth factor-1Resolvin D1Specialized pro-resolving mediatorsTenascin-C

Identifiers

PMID40764724
PMCPMC12325681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.